Table 3. Adiponectin receptor 1 expression.
| Lean controls | Obese-pre | Obese-post | |
|---|---|---|---|
| Innate immunity | |||
| Monocytes (total) | 21 (18–31) | 31 (18–36) | 25 (20–29) |
| CD14++CD16- | 10 (8.8–16) # | 8.2 (4.6–27) | 7.7 (3.7–11) # |
| CD14++CD16+ | 82 (68–88) | 90 (81–94) | 84 (73–93) |
| CD14+CD16++ | 84 (71–92) * | 94 (77–98) * | 91 (85–96) |
| Natural Killer cells (CD16+CD56+) | 82 (56–92) | 86 (76–95) | 88 (78–95) |
| CD16+CD56++ | 41 (29–63) | 51 (39–58) | 56 (44–64) |
| CD16-CD56++ | 1.6 (0.5–3.1) | 0.9 (0.1–4.6) | 0.8 (0.4–1.8) |
| Bridging immunity | |||
| Natural Killer T cells | 7.6 (4.1–25) | 12 (4.1–18) | 6.9 (5.0–15) |
| Adaptive immunity | |||
| B cells | |||
| Naive (CD10-CD27-) | 1.1 (0.6–2.2) # | 0.8 (0.5–2.0) | 0.5 (0.4–1.0) # |
| Memory (CD10-CD27+) | 5.9 (3.8–6.6) | 5.6 (3.8–8.8) | 6.4 (3.5–9.6) |
| Immature transition (CD10+CD27+) | 0.0 (0.0–0.2) * | 0.7(0.3–1.0) *$ | 0.1 (0.0–0.5) $ |
| CD4+ T helper cells | |||
| CD45RO- CXCR3- | 5.2 (1.6–21) | 3.3 (1.0–22) | 3.6 (1.6–19) |
| CD45RO- CXCR3+ | 64 (45–92) | 47 (37–71) | 63 (49–81) |
| CD45RO+ CXCR3- | 6.1 (2.1–12) | 4.7 (1.6–12) | 6.6 (2.2–11) |
| CD45RO+ CXCR3+ | 24 (12–38) | 21 (12–42) | 41 (16–56) |
| CD8+ cytotoxic T cells | |||
| CD45RO- CCR7- | 46 (41–55) | 51 (42–61) | 50 (42–61) |
| CD45RO- CCR7+ | 60 (55–74) | 54 (45–66) | 53 (46–68) |
| CD45RO+ CCR7- | 34(30–43) | 36 (31–52) | 38 (34–43) |
| CD45RO+ CCR7+ | 70 (66–77) | 68 (52–90) | 72 (67–87) |
| Regulatory T cells (CD25+CD127-) | 3.9 (1.6–14) | 4.0 (1.0–9.0) | 4.8 (1.6–9.7) |
Percentage expression of adiponectin receptor 1 on leukocyte subsets of lean controls compared to obese children pre-lifestyle intervention (pre) and post-lifestyle intervention (post). Data are presented as median (interquartile range).
* p<0.05 for lean controls compared to obese-pre.
# p<0.05 for lean controls versus obese-post.
$ p<0.05 for obese-pre compared to obese-post.